Clay Siegall a Household Name in Cancer Research and Treatment
Clay Siegall aged 56, is the co-founder of Seattle Genetics, the CEO as well as the president. Clay worked with Bristol-Myers Squibb Pharmaceutical Research Institute as the senior research investigator from 1991 February to 1995 January. He later worked as the principal scientist in the same organization from January 1995 to December 1997. After the inception of Seattle Genetics Inc., he served as the executive vice president from 1997 to 2000 and the chief scientific officer from 1997 December to 2002 November.
Dr. Siegall has made major milestones in his cancer research; Clay has dedicated his life to ensuring that cancer patients receive the best treatment. Clay Siegall has become a household name, and his work has not gone unnoticed. Various blogs and publications have praised Clay as a dedicated doctor on the front line to fight cancer after his father was diagnosed with brain cancer.
Clay has been in cancer research for two decades now; he is also an author of almost 70 publications as well as a blog.
Dr. Clay’s contribution as CEO.
Clay’s leadership style and skills have brought several advantages to the organization, recent studies have shown that Seattle Genetics has raised its stock price almost three times higher, this is a great milestone for the company. The company also received approval for antibody cancer treatments by US Food and Drug Administration.
As the CEO, Clay Siegall’s responsibility is to foster good relations with other related companies to assist with activities. Clay works closely with The Fred Hutchinson Cancer Research Business Alliance, where he is a Board of Governors, The Washington Biotechnology and Biomedical Association and Alder Biopharmaceuticals, a biotechnology company, where he serves as Board of Directors. These alliances have contributed significantly to the success of Seattle Genetics as well as cancer treatment and research.
Clay’s role in the cancer research community.
Clay Siegall has worked in several companies, but one that has shaped his career is the National cancer institute where he was involved with research, this institution helped sharpen his skills and helped him gain experience in cancer research as well as therapeutic cancer treatment. Clay also advanced an older treatment antibody-drug conjugates that are used all over the world and is used in over 65 countries as treatment.